Metal nanoparticles (NPs) have garnered considerable attention, due to their unique physicochemical properties, that render them promising candidates for various applications in medicine and industry. This article offers a comprehensive overview of the most recent advancements in the manufacturing, characterization, and biomedical utilization of metal NPs, with a primary focus on silver and gold NPs. Their potential as effective anticancer, anti-inflammatory, and antimicrobial agents, drug delivery systems, and imaging agents in the diagnosis and treatment of a variety of disorders is reviewed. Moreover, their translation to therapeutic settings, and the issue of their inclusion in clinical trials, are assessed in light of over 30 clinical investigations that concentrate on administering either silver or gold NPs in conditions ranging from nosocomial infections to different types of cancers. This paper aims not only to examine the biocompatibility of nanomaterials but also to emphasize potential challenges that may limit their safe integration into healthcare practices. More than 100 nanomedicines are currently on the market, which justifies ongoing study into the use of nanomaterials in medicine. Overall, the present review aims to highlight the potential of silver and gold NPs as innovative and effective therapeutics in the field of biomedicine, citing some of their most relevant current applications.

The most prevalent neurodegenerative disease is Alzheimer's dementia. It is determined by the deposits of amyloid-beta peptide which leads to memory impairment, oxidative stress, and neurodegeneration. Aromatherapy by using essential oils could represent a natural treatment option for Alzheimer's dementia. Therefore, this study aimed to identify the neuroprotective and nootropic effects of Pinus halepensis essential oil (PNO, 1% and 3%, administered for three weeks) in a rat model of acute amyloid beta (1-42) (Aβ1-42) toxicity. Rats were behaviorally tested (radial arm maze and Y-maze activities being used). Rats were divided into five groups (n = 5 / group): first group - vehicle, second group - Aβ1-42, the third and fourth group - PNO treatment groups (1% and 3%), and fifth group - donepezil group (as positive control, 5 mg/kg injected in Aβ1-42-treated rats). Antioxidant activity of the investigated essential oil was assessed using radical scavenging assays, such as 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 3-ethylbenzothiazoline-6-sulfonic acid (ABTS) tests. Also, biochemical estimations of the brain homogenates for acetylcholinesterase and oxidative stress biomarkers were carried out. The essential oil reversed the amyloid beta (1-42)-induced decreasing of the spontaneous alternation in the Y-maze test and the amyloid beta (1-42)-induced increasing of the working and reference memory errors in the radial arm maze test. The amyloid beta (1-42)-induced modification of the balance oxidant-antioxidant and acetylcholinesterase action in the hippocampus of the rat has been ameliorated using the essential oil. These findings suggested that Pinus halepensis essential oil has nootropic and neuroprotective activities and may be regarded as a therapeutic tool for attenuation of Aβ toxicity and neuronal dysfunction.